# Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

> **NCT03843294** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Catherine Bollard** · enrollment: 18 (estimated)

## Conditions studied

- Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** TAA-T cells
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03843294
- **Lead sponsor:** Catherine Bollard
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-24
- **Primary completion:** 2023-05-02
- **Final completion:** 2026-08
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843294, "Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03843294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*